Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 10, 2018

AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial

AstraZeneca said that the combination of its Imfinzi (durvalumab) monotherapy and tremelimumab has failed to improve overall survival (OS) rate compared to standard-of-care (SoC) chemotherapy in a head and neck cancer trial.

Image: AstraZeneca’s Imfinzi has failed to improve OS in head and neck cancer trial. Photo: courtesy of AstraZeneca.